Antibiotics for treatment of resistant gram-positive coccal infections

被引：8

作者：

Hossam Al-Tatari

Nahed Abdel-Haq

Pimpanada Chearskul

Basim Asmar

机构：

[1] Wayne State University School of Medicine,Carman and Ann Adams Department of Pediatrics

[2] Children's Hospital of Michigan,Division of Infectious Diseases

来源：

The Indian Journal of Pediatrics | 2006年 / 73卷 / 4期

关键词：

Vancomycin; Gram-positive; Bacterial infections; Antibacterial agents;

D O I：

10.1007/BF02825827

中图分类号：

学科分类号：

摘要：

Vancomycin is considered the workhorse for the treatment of most drug-resistant gram-positive bacterial infections. However, concerns have been raised regarding the increasing rates of vancomycin-resistant enterococci and the clinical shortcomings of vancomycin in the treatment of invasiveStaphylococcus aureus infections. Resources have been committed to the development of antimicrobial agents with activity against these organisms. This review will focus on the newer antibacterial agents that have been developed for the treatment of resistant gram-positive pathogens. Included in this review are the agents: quinupristin-dalfopristin, linezolid, daptomycin, telithromycin, and tigecycline.

引用

页码：323 / 334

页数：11

共 346 条

[61]

Hutchinson D(2002)Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas Scand J Infect Dis 34 823-826

[62]

Barbachyn M(2001) activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae Antimicrob Agents Chemother 45 170-175

[63]

Daly JS(2003) activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia Int J Antimicrob Agents 21 441-445

[64]

Eliopoulos GM(2002)Telithromycin Drugs 62 1771-804

[65]

Willey S(2001)Relative potency of telithromycin, azithromycin and erythromycin against recent clinical isolates of gram-positive cocci Clin Microbiol Infect 7 24-9

[66]

Moellering RC(2001) pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori Pharmacotherapy 21 1204-1222

[67]

Lin AH(2002) activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis Expert Opin Pharmacother 3 277-297

[68]

Murray RW(2001)Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin Curr Opin Investig Drugs 2 1691-701

[69]

Vidmar TJ(2001)Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses Scand J Infect Dis 33 883-890

[70]

Marotti KR(2004)Telithromycin (HMR 3647) achieves high and sustained concentrations in tonsils of patients undergoing tonsillectomy Clin Ther 26 704-714

← 2 3 4 5 6 7 8 9 10 11 →